Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.63 |
| ▸ | PARP1 | P09874 | 6/20 | 0.63 |
| ▸ | F7 | P08709 | 1/20 | 0.58 |
| ▸ | F3 | P13726 | 1/20 | 0.58 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.55 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438649 | 1.00 | PARP10 (0.63) | PARP10PARP1F7F3RYR2 | |
| SCHEMBL1649500 | 0.90 | MAPKAPK2 (0.57) | PARP10PARP1F7F3RYR2 | |
| SCHEMBL8323443 | 0.87 | GRM5 (0.67) | PARP10PARP1RYR2GRM5MAPKAPK2 | |
| SCHEMBL379341 | 0.87 | GRM5 (0.67) | PARP10PARP1RYR2GRM5MAPKAPK2 | |
| SCHEMBL31069587 | 0.83 | PDE3B (0.53) | RYR2MAPKAPK2ALDH1A1KDM4EHPGD | |
| SCHEMBL2849831 | 0.83 | PDE3B (0.53) | RYR2MAPKAPK2ALDH1A1KDM4EHPGD | |
| SCHEMBL22451527 | 0.82 | RYR2 (0.56) | PARP10PARP1RYR2GRM5MAPKAPK2 | |
| SCHEMBL23537819 | 0.81 | CSNK1A1 (0.52) | PARP10PARP1F7F3RYR2 | |
| SCHEMBL25687365 | 0.80 | HTR2C (0.45) | GRM5ALDH1A1KDM4EMAPTACHE | |
| SCHEMBL30947279 | 0.80 | PARP10 (0.58) | PARP10PARP1F7F3RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688772-A1 | BIARYL DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024211834-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024086809-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4215524-A1 | COMPOUND SERVING AS THYROID HORMONE BETA RECEPTOR AGONIST AND USES OF COMPOUND | Sunshine Lake Pharma Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| EP-0526402-B1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA GEIGY AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| EP-0779887-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | disclosed |
| US-5401756-A | Benzamide platelet activating factor antagonists | MITSUBISHI KASEI CORPORATION (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5350761-A | Lipoxygenase inhibitors as antiinflammatory agents and antiallergens | CIBA-GEIGY CORPORATION (US) | 1994-09-27 | — | — | US | disclosed |
| US-5334600-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| US-5304556-A | Platelet activating factor antagonists | MITSUBISHI KASEI CORPORATION (JP) | 1994-04-19 | — | — | US | disclosed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0548934-A1 | Benzamide derivatives | Mitsubishi Chemical Corporation (JP) | 1993-06-30 | — | — | EP | disclosed |
| EP-0526402-A1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA-GEIGY AG (CH) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | PARP10 4291/4885PARP1 4762/4885F7 2154/4885 |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | PARP10 878/4885PARP1 277/4885F7 1140/4885 |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HAVCR2, CYP7A1, CYP26B1 | PARP10 3577/4885PARP1 2730/4885F7 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.